Glucose Transporter 1 Deficiency as a Treatable Cause of Myoclonic Astatic Epilepsy
Saul A Mullen, Carla Marini, Arvid Suls, Davide Mei, Elvio Della Giustina, Daniela Buti, Tudor Arsov, John Damiano, Kate Lawrence, Peter De Jonghe, Samuel F Berkovic, Ingrid E Scheffer, Renzo Guerrini
Archives of Neurology | AMER MEDICAL ASSOC | Published : 2011
Dr Berkovic has served on scientific advisory boards for UCB and Janssen-Cilag EMEA; has received funding for travel and honoraria from UCB; serves/has served on the editorial boards of Brain and Epileptic Disorders; and has received research support from UCB, the National Health and Medical Research Council of Australia, and the American Epilepsy Society. Dr Scheffer has served an scientific advisory boards for UCB and Janssen-Cilag EMEA; serves on the editorial boards of the Annals of Neurology and Epileptic Disorders; may accrue future revenue on pending patent WO61/010176 (filed in 2008): Therapeutic Compound; has received speaker honoraria from Athena Diagnostics, UCB, Janssen-Cilag EMEA, and Eli Lilly and Company; has received funding for travel from Athena Diagnostics, UCB, and Janssen-Cilag EMEA; and receives/has received research support from the National Health and Medical Research Council of Australia, the Health Research Council of New Zealand, the University of Melbourne, the American Epilepsy Society, the Jack Brockhoff Foundation, the Shepherd Foundation, and the Perpetual Charitable Trustees.Funding was provided by the National Health and Medical Research Council of Australia, the Methusalem Excellence Grant of the Flemish Government, and the European Union (EPICURE project). Additional Contributions: We thank the patients and their families for participating in our research. We also thank the VIB Genetic Service Facility (http://www.vibgeneticservicefacility.be) for the genetic analyses.